ES2733128T3 - Inhibidor de fosfoinosítido 3-quinasa con un resto de unión a cinc - Google Patents

Inhibidor de fosfoinosítido 3-quinasa con un resto de unión a cinc Download PDF

Info

Publication number
ES2733128T3
ES2733128T3 ES16166266T ES16166266T ES2733128T3 ES 2733128 T3 ES2733128 T3 ES 2733128T3 ES 16166266 T ES16166266 T ES 16166266T ES 16166266 T ES16166266 T ES 16166266T ES 2733128 T3 ES2733128 T3 ES 2733128T3
Authority
ES
Spain
Prior art keywords
compound
tumor
cancer
cells
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16166266T
Other languages
English (en)
Spanish (es)
Inventor
Cai Xiong
Haixiao Zhai
Chengjung Lai
Changgeng Qian
Rudi Bao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curis Inc
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Application granted granted Critical
Publication of ES2733128T3 publication Critical patent/ES2733128T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES16166266T 2011-04-01 2012-03-30 Inhibidor de fosfoinosítido 3-quinasa con un resto de unión a cinc Active ES2733128T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161470849P 2011-04-01 2011-04-01
US201161559489P 2011-11-14 2011-11-14

Publications (1)

Publication Number Publication Date
ES2733128T3 true ES2733128T3 (es) 2019-11-27

Family

ID=46931927

Family Applications (2)

Application Number Title Priority Date Filing Date
ES16166266T Active ES2733128T3 (es) 2011-04-01 2012-03-30 Inhibidor de fosfoinosítido 3-quinasa con un resto de unión a cinc
ES12764605.7T Active ES2577982T3 (es) 2011-04-01 2012-03-30 Inhibidor de fosfoinosítido 3-quinasa con un resto de unión a cinc

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES12764605.7T Active ES2577982T3 (es) 2011-04-01 2012-03-30 Inhibidor de fosfoinosítido 3-quinasa con un resto de unión a cinc

Country Status (30)

Country Link
US (7) US8710219B2 (hr)
EP (2) EP3111938B1 (hr)
JP (3) JP6242331B2 (hr)
KR (2) KR20180108848A (hr)
CN (2) CN103582483B (hr)
AU (1) AU2012236367B2 (hr)
BR (1) BR112013025340B1 (hr)
CA (1) CA2830822C (hr)
CL (1) CL2013002823A1 (hr)
CY (2) CY1117785T1 (hr)
DK (2) DK3111938T3 (hr)
EA (1) EA022434B9 (hr)
ES (2) ES2733128T3 (hr)
HK (1) HK1194969A1 (hr)
HR (2) HRP20160545T1 (hr)
HU (2) HUE045041T2 (hr)
IL (2) IL228588A (hr)
LT (1) LT3111938T (hr)
ME (2) ME02451B (hr)
MX (1) MX340577B (hr)
PE (1) PE20141382A1 (hr)
PL (2) PL2694075T3 (hr)
PT (2) PT3111938T (hr)
RS (2) RS54903B1 (hr)
SG (2) SG10201602569RA (hr)
SI (2) SI3111938T1 (hr)
SM (1) SMT201600179B (hr)
TW (1) TWI571469B (hr)
WO (1) WO2012135571A1 (hr)
ZA (2) ZA201307082B (hr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA024252B1 (ru) 2009-01-08 2016-08-31 Кьюрис, Инк. Ингибиторы фосфоинозитид-3-киназ с цинксвязывающей группой
AU2012236367B2 (en) * 2011-04-01 2014-10-09 Curis, Inc. Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
SG10201510307WA (en) 2011-11-14 2016-01-28 Cephalon Inc Uracil derivatives as axl and c-met kinase inhibitors
CN104725301A (zh) * 2013-12-20 2015-06-24 北京蓝贝望生物医药科技股份有限公司 一种1,2-二氢吡啶-2-酮衍生物的制备方法
ES2833473T3 (es) * 2015-04-21 2021-06-15 Chengdu Zenitar Biomedical Tech Co Ltd Derivados de purinil-N-hidroxil pirimidin formamida, método de preparación y uso de los mismos
WO2018015895A1 (en) * 2016-07-19 2018-01-25 National Institute Of Plant Genome Research Novel protein against fungal pathogens
AU2017355385A1 (en) * 2016-11-02 2019-05-30 Curis, Inc. Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
AU2018360845B2 (en) * 2017-11-06 2024-05-02 Cold Spring Harbor Laboratory Method and compositions for forming a copper-containing complex and uses thereof
KR20210087438A (ko) 2018-09-11 2021-07-12 쿠리스 인코퍼레이션 아연 결합 모이어티를 가진 포스포이노시티드 3-키나제 저해제를 이용한 병용 요법
WO2023212574A1 (en) * 2022-04-26 2023-11-02 Olivia Szu Hsieh Lee Nakaya Compositions and methods for modulating rhythmic activity of pacemaker cardiomyocytes

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4828991A (en) 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5502187A (en) 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
US5508269A (en) 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US6083922A (en) 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
US5767068A (en) 1997-02-13 1998-06-16 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
WO2001083456A1 (fr) 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Derives d'heteroaryle condenses
PL213783B1 (pl) 2002-03-13 2013-05-31 Janssen Pharmaceutica Nv Podstawiona pochodna piperydyny lub piperazyny, jej zastosowanie i sposób wytwarzania oraz kompozycja farmaceutyczna
ES2306858T3 (es) 2002-03-13 2008-11-16 Janssen Pharmaceutica Nv Derivados de carbonilamino como nuevos inhibidores de las histonadesacetilasas.
US7205304B2 (en) 2002-03-13 2007-04-17 Janssen Pharmaceutica N.V. Sulfonyl-Derivatives as novel inhibitors of histone deacetylase
ATE396971T1 (de) 2002-03-13 2008-06-15 Janssen Pharmaceutica Nv Sulfonylaminoderivate als neue inhibitoren von histondeacetylase
AU2003255845A1 (en) 2002-08-22 2004-03-11 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
NZ541772A (en) 2003-01-29 2009-10-30 Takeda Pharmaceutical Thienopyrimidine compounds and use thereof
AU2005230682B2 (en) * 2004-04-05 2010-10-21 Merck Hdac Research, Llc Histone deacetylase inhibitor prodrugs
EP1750727A2 (en) 2004-04-23 2007-02-14 Exelixis, Inc. Kinase modulators and methods of use
CA2583259C (en) 2004-10-08 2011-08-02 Astellas Pharma Inc. Aromatic ring fused pyrimidine derivative
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
EP1855760A2 (en) 2005-02-03 2007-11-21 TopoTarget UK Limited Combination therapies using hdac inhibitors
DK1885710T3 (en) 2005-05-18 2015-11-23 Janssen Pharmaceutica Nv SUBSTITUTED AMINOPROPENYLPIPERIDINE OR MORPHOLINE DERIVATIVES AS UNKNOWN INHIBITORS OF HISTONDEACETYLASE
ES2376121T3 (es) 2006-01-19 2012-03-09 Janssen Pharmaceutica, N.V. Derivados de heterociclilalquilo como nuevos inhibidores de histona deacetilasa.
CA2630717C (en) 2006-01-19 2015-02-24 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
WO2007082880A1 (en) 2006-01-19 2007-07-26 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
AU2007243457B2 (en) 2006-04-26 2012-02-23 F. Hoffmann-La Roche Ag Pharmaceutical compounds
TW200801012A (en) * 2006-04-26 2008-01-01 Piramed Ltd Phosphoinositide 3-kinase inhibitor compounds and methods of use
US7781433B2 (en) 2006-04-26 2010-08-24 Piramed Limited Pharmaceutical compounds
EP2018366A4 (en) 2006-05-16 2010-08-04 Univ Mcgill HYBRID MOLECULES HAVING MIXED PROPERTIES OF VITAMIN D RECEPTOR AGONISM AND HISTONE DEACETYLASE INHIBITOR
KR101433629B1 (ko) 2006-09-11 2014-08-27 쿠리스 인코퍼레이션 아연 결합 부분을 함유한 티로신 키나아제 억제제
CN101535279B (zh) 2006-09-11 2015-05-20 柯瑞斯公司 含锌结合基的喹唑啉基egfr抑制剂
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
WO2008033745A2 (en) 2006-09-11 2008-03-20 Curis, Inc. Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
CA2663147A1 (en) 2006-09-11 2008-03-20 Curis, Inc. Substituted 2-indolinone as ptk inhibitors containing a zinc binding moiety
EP2061772A4 (en) 2006-09-11 2011-06-29 Curis Inc MULTIFUNCTIONAL SMALL MOLECULES AS PROLIFERATION-ACTIVE ACTIVE SUBSTANCES
CN101573333B (zh) 2006-10-28 2013-06-12 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
MY180595A (en) 2006-12-07 2020-12-03 Genentech Inc Phosphoinositide 3-kinase inhibitor compounds and methods of use
US9487533B2 (en) * 2006-12-07 2016-11-08 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and methods of use
RU2009134223A (ru) 2007-02-15 2011-03-20 Новартис АГ (CH) Комбинация lbh589 с другими терапевтическими средствами, предназначенная для лечения рака
US20080234332A1 (en) 2007-03-20 2008-09-25 Xiong Cai Raf kinase inhibitors containing a zinc binding moiety
WO2009036066A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Vegfr inhibitors containing a zinc binding moiety
WO2009036057A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Antiproliferative agents containing a zinc binding moiety
WO2009036020A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Mek inhibitors containing a zinc binding moiety
TW200922564A (en) 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
TW200922590A (en) 2007-09-10 2009-06-01 Curis Inc VEGFR inhibitors containing a zinc binding moiety
US8247397B2 (en) 2007-09-12 2012-08-21 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
WO2009042646A1 (en) 2007-09-24 2009-04-02 Curis, Inc. Anti-proliferative agents
US8354528B2 (en) 2007-10-25 2013-01-15 Genentech, Inc. Process for making thienopyrimidine compounds
WO2009058895A1 (en) 2007-10-30 2009-05-07 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac and an mtor inhibitor
WO2009086012A1 (en) 2007-12-20 2009-07-09 Curis, Inc. Aurora inhibitors containing a zinc binding moiety
US20110178070A1 (en) 2008-06-24 2011-07-21 Takeda Pharmaceutical Company Limited PI3K/mTOR INHIBITORS
WO2009155659A1 (en) 2008-06-27 2009-12-30 The University Of Queensland Combination therapy
US8196911B2 (en) 2008-10-27 2012-06-12 Honda Motor Co., Ltd. Adjustable rate subframe mount
EA024252B1 (ru) * 2009-01-08 2016-08-31 Кьюрис, Инк. Ингибиторы фосфоинозитид-3-киназ с цинксвязывающей группой
JP5844159B2 (ja) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
BRPI1006189A2 (pt) 2009-03-12 2020-08-18 Genentech Inc uso de uma combinação terapêutica, formulação farmacêutica, artigo de manufatura, produto, método para determinar compostos a serem utilizados em combinação para o tratamento de uma malignidade hematopoiética e método para selecionar compostos a serem utilizados em combinação para o tratamento de câncer
EP2488178B1 (en) 2009-10-12 2016-11-16 F.Hoffmann-La Roche Ag Combinations of a pi3k inhibitor and a mek inhibitor
AU2011239537A1 (en) * 2010-04-16 2012-11-15 Curis, Inc. Treatment of cancers having K-ras mutations
AU2012236367B2 (en) * 2011-04-01 2014-10-09 Curis, Inc. Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
US20130102595A1 (en) 2011-04-15 2013-04-25 Curis, Inc. Treatment of cancers having k-ras mutations
TW201840336A (zh) 2011-08-01 2018-11-16 美商建南德克公司 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
JP6980980B2 (ja) 2015-06-25 2021-12-15 イミューノメディクス、インコーポレイテッドImmunomedics, Inc. 抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する
AU2017355385A1 (en) * 2016-11-02 2019-05-30 Curis, Inc. Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety

Also Published As

Publication number Publication date
US11135205B2 (en) 2021-10-05
US20130090335A1 (en) 2013-04-11
HRP20191091T1 (hr) 2019-09-20
NZ705039A (en) 2016-03-31
US9249156B2 (en) 2016-02-02
PE20141382A1 (es) 2014-11-04
ME02451B (me) 2016-09-20
AU2012236367A1 (en) 2013-04-18
US10111864B2 (en) 2018-10-30
HRP20160545T1 (hr) 2016-06-17
BR112013025340B1 (pt) 2021-12-21
PT3111938T (pt) 2019-07-10
SMT201600179B (it) 2016-08-31
CL2013002823A1 (es) 2014-04-11
EP2694075B1 (en) 2016-04-27
US8710219B2 (en) 2014-04-29
EA022434B1 (ru) 2015-12-30
IL228588A0 (en) 2013-12-31
ZA201406167B (en) 2015-03-25
WO2012135571A1 (en) 2012-10-04
JP6275784B2 (ja) 2018-02-07
DK2694075T3 (en) 2016-08-01
EP3111938B1 (en) 2019-05-08
EP3111938A1 (en) 2017-01-04
US20170304279A1 (en) 2017-10-26
JP2014509653A (ja) 2014-04-21
SG10201602569RA (en) 2016-05-30
MX340577B (es) 2016-07-13
US20160185796A1 (en) 2016-06-30
US20220168284A1 (en) 2022-06-02
CY1117785T1 (el) 2017-05-17
EA201301114A1 (ru) 2014-04-30
HUE028910T2 (en) 2017-01-30
HUE045041T2 (hu) 2019-12-30
US20200215039A1 (en) 2020-07-09
KR20140023333A (ko) 2014-02-26
JP2018052987A (ja) 2018-04-05
IL228588A (en) 2016-11-30
US11654136B2 (en) 2023-05-23
US10543197B2 (en) 2020-01-28
CA2830822C (en) 2018-10-02
PL2694075T3 (pl) 2016-09-30
MX2013011132A (es) 2014-03-12
US20190091211A1 (en) 2019-03-28
IL248597A0 (en) 2016-12-29
JP2016188255A (ja) 2016-11-04
IL248597B (en) 2018-04-30
RS59219B1 (sr) 2019-10-31
KR101902325B1 (ko) 2018-09-28
CN103582483B (zh) 2016-02-17
CY1121825T1 (el) 2020-07-31
ES2577982T3 (es) 2016-07-19
SG193563A1 (en) 2013-11-29
US9657032B2 (en) 2017-05-23
TWI571469B (zh) 2017-02-21
PL3111938T3 (pl) 2019-09-30
ME03523B (me) 2020-04-20
CA2830822A1 (en) 2012-10-04
US20140243330A1 (en) 2014-08-28
LT3111938T (lt) 2019-06-25
RS54903B1 (sr) 2016-10-31
DK3111938T3 (da) 2019-07-01
ZA201307082B (en) 2015-04-29
AU2012236367B2 (en) 2014-10-09
HK1194969A1 (zh) 2014-10-31
BR112013025340A2 (pt) 2016-12-13
JP6242331B2 (ja) 2017-12-06
KR20180108848A (ko) 2018-10-04
EP2694075A4 (en) 2014-10-01
CN103582483A (zh) 2014-02-12
PT2694075T (pt) 2016-07-11
NZ615586A (en) 2015-02-27
SI3111938T1 (sl) 2019-08-30
CN105461736B (zh) 2018-06-12
SI2694075T1 (sl) 2016-07-29
CN105461736A (zh) 2016-04-06
EA022434B9 (ru) 2016-02-29
TW201247678A (en) 2012-12-01
EP2694075A1 (en) 2014-02-12

Similar Documents

Publication Publication Date Title
ES2733128T3 (es) Inhibidor de fosfoinosítido 3-quinasa con un resto de unión a cinc
ES2550032T3 (es) Inhibidores de fosfoinosítido 3-quinasa con un resto de unión a cinc
AU2014280913A1 (en) Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
NZ705039B2 (en) Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
NZ615586B2 (en) Phosphoinositide 3-kinase inhibitor with a zinc binding moiety